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ABSTRACT  
Therapeutic nucleic acids demand specificity and accuracy in design as well as delivery strategies used in replacement or silencing of the target 
gene. Gene therapy is believed to be the therapy in which the root cause of the diseases can be treated at the molecular level. Generally gene therapy 
helps in the identification of the origin of the disorder instead of using drugs to diminish or control the symptoms. The application of nucleic acids to 
treat and control diseases is known as “gene therapy.” Gene therapy consists on the substitution or addition of a functional gene into the nucleus of 
a living cell, in order to treat a disease or repair a dysfunction, caused by this gene failure. This therapy is used to correct defective genes, which are 
responsible for genetic diseases. Thus, gene therapy can be used to prevent, treat or regulate hereditary or acquired disorders, by the production of 
therapeutic proteins. The gene therapy is mediated by the use of viral and non-viral vectors to transport foreign genes into somatic cells to 
restorative defective genes. This review focuses on viral vectors in detail. 
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INTRODUCTION 
Nucleic acids (NA) therapies have been gaining significant scientific 
and clinical interest over the last two decades. The main reasons for 
the failure are the occurrence of unexpected severe adverse effects 
during clinical trials, and the difficulties to accomplish a successful 
administration of deoxyribonucleic acid (DNA) and ribonucleic acid 
(RNA) molecules within the human body, related to the difficulties of 
targeting the cell’s nucleus. Currently, several gene therapy 
medicines are approved for clinical use, especially in severe diseases 
(e. g., cancer and AIDS), where the benefit-risk balance accepted for 
therapeutic is small, compared to other less serious diseases. 
Basically, NA therapy consists of two parts: first, the therapeutic NA 
itself, with plasmid DNA (pDNA) and different types of small RNA, and 
second, the carrier which delivers the NA to the desired site, including 
viral and non-viral vectors [1]. Nucleic acids, such as pDNA, antisense 
oligonucleotide, and RNA molecules, have a great potential to be used 
as therapeutics for the treatment of various genetic and acquired 
diseases [2]. Several strategies are being explored for their enhanced 
gene transfer, including design of different synthetic carriers [3] or the 
use of physical approaches [4]. Gene therapy emerged as the gold 
standard when two Nobel prizes were acclaimed by Andrew Fire and 
Craig Mello, who demonstrated the mechanism and application of RNA 
interference (RNAi) in 2006 [5]. Basically, gene therapy treatment 
involves three steps [6] as shown in fig. 1. 
Furthermore, for a successful gene therapy process, an appropriate 
amount of the therapeutic gene (i.e. the transgene) must be 
delivered into the target tissue or cell, without exerting significant 
toxicity. Generally, two categories of gene therapy have emerged, the 
germ line and somatic gene therapy. The former consists in 
transferring the functional gene into germ cells, which means that it 
will be integrated in the individual genome, passing through 
generations. In the somatic gene therapy, the functional gene is 
introduced only in a specific target cell’s (somatic cell’s), without 
transmission of hereditary to the next generations. Currently, gene 
therapy offers new treatment possibilities for both acquired and 
hereditary diseases where conventional clinical procedures are less 
effective, such as cystic fibrosis, cancer, arthritis, peripheral vascular 
diseases, neurodegenerative disorders and AIDS [7]. Hereditary 
diseases are generally caused by deletion or mutation of a single cell, 
whereas in acquired diseases, a single gene cannot be defined as the 
only cause of disease [8]. 
 
Fig. 1: Steps involved in gene therapy 
 
Barriers to the nucleic acid delivery 
In the context of efficient delivery of nucleic acids, it should fulfill 
two of the most important criteria, namely, safety and efficacy [9]. 
One of the challenges to the systemic delivery of nucleic acid 
therapeutics is the potential degradation of the NA by end nucleases 
in physiological fluids and the extracellular space [10]. Among all of 
the challenges in the delivery of nucleic acids, some important 
challenges are described and should be considered while designing 
the appropriate delivery approach (fig. 2). 
Intracellular bioavailability 
With the introduction of nucleic acids (naked or encapsulated form) 
in biological fluids faces many physiological or biological barriers 
leading to altered cellular bio distribution as well as overall 
intracellular bioavailability. Unmodified DNA and RNA, whether it 
may be a plasmid, siRNA, or shRNA, rapidly degrade in biological 
fluids by various extra-and intracellular enzymes before they can 
reach the surface of the target cells; this administration ultimately 
leads to the loss of therapeutic activity of nucleic acid [11] and poses 
a challenge to the effective delivery. 
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Fig. 2: Challenges while designing the appropriate delivery approach 
 
Induction of immune response 
The exogenously administered nucleic acid materials may trigger 
and activate the immune system, resulting in the release of 
inflammatory cytokines, which may lead to serious local and 
systemic inflammatory reactions [12]. The endosomal toll-like 
receptors (TLRs) are the most commonly identified mechanisms 
involved in the release of the pro-inflammatory cytokines. This 
immune mechanism can be augmented by the complexation of 
nucleic acid with cationic polymer or some lipids [13]. 
Low nuclear uptake 
It is evident that there must be translocation between plasmid and 
nucleic acid for gene expression without considering the types of carrier 
and internalization pathways. Translocation, which involves both 
trafficking to the nucleus and penetration of the nuclear membrane 
through naked DNA or RNA into the nucleus, is usually ineffectual in 
both dividing and non-dividing cells. As per Bieber et al., (2002), only a 
small fraction of DNA/polyethyleneimine (PEI) complexes, which are 
internalized by the cells and released from the endosomes, successfully 
reaches inside the nucleus [14]. The characteristic of nuclear membrane 
permeability and the translocation process of the nucleus allow the 
import and export of specific molecules into and out of the nucleus [15]. 
Due to the membrane pore size (25 nm), molecules smaller than 40 kDa 
or complexes with a particle size of 25 nm can diffuse passively, whereas 
larger molecules cannot diffuse [16]. 
Extracellular and intracellular barriers in nucleic acid delivery 
It is difficult to achieve the desired therapeutic effect of nucleic acid 
delivery by conventional delivery strategies due to several biological 
and cellular barriers (fig. 3) present in the body. Before reaching the 
targeted site, NAs face many obstacles to go across extracellular, 
cellular, and intracellular biological membranes [17]. Following 
systemic administration, these molecules have to go across various 
intracellular barriers such as intracellular trafficking, endosomal 
escape, and extracellular barriers like lipid bilayer membrane and 
various endothelial barriers [18]. 
The next barrier is the lack of techniques to study the intracellular 
trafficking of polyplexes to probe and elucidate steps that limit 
transfection efficiency [19]. 
 
 
Fig. 3: Different types of biological barriers in nucleic acid delivery 
Usually, the gene therapy is mediated by the use of viral and non-
viral vectors to transport foreign genes into somatic cells to 
restorative defective genes [20]. Antisense oligonucleotide (AON), 
siRNA, and pDNA are the important types of nucleic acids for gene 
therapy which are principally utilized as potent therapeutic agents 
to silence the expressions of defective genes. Following paragraphs 
details of all three important types of nucleic acid delivery tools. 
Plasmid DNA 
Plasmid is a unique type of double-stranded DNA, usually circular in 
shape, used in gene therapy, and it contains the transgene that 
encodes for a specific protein. The size of the most commonly used 
pDNA ranges from a few hundred base pairs (bp) to several thousand 
bp [21]. Therapeutically, plasmids can be used for the treatment of 
several diseases, as well as an active constituent for vaccination. 
Promoter and enhancer sequences in pDNA, as regulatory signals, play 
an important role in regulating gene expression [22]. Promoter 
sequences are derived from viral origin such as cytomegalovirus and 
roux sarcoma virus, which initiate the transcription process by acting 
as a recognition site for the RNA polymerase which ensures high 
transcription efficiency. Enhancers are the regions in the pDNA that 
can be upstreamed or downstream from the promoter region. They act 
as binding sites for proteins that enhance the initiation of gene 
transcription. The selection of a suitable enhancer can improve 
transcription efficiency by several hundred folds [23, 24]. 
Antisense oligonucleotide 
According to the idea of using block protein function as a drug 
molecular mechanism for treating diseases, antisense 
oligonucleotide therapy was developed. These oligonucleotides 
consist of small strands of DNA or RNA that can hybridize with 
specific DNA or mRNA (i.e. messenger RNA) sequences and suppress 
gene expression. The sequence of DNA or RNA that encodes the 
information for the protein production is called sense strand. In the 
double-strand DNA molecule, a complementary sequence is called 
antisense strand. Accordingly, it is possible to chemically synthesize 
antisense strands of nucleotides, which can bind with high level of 
affinity, i.e. selectively hybridize, to specific sense DNA or RNA 
strands, by Watson-Crick base-pairing rules. As a consequence, the 
process of DNA transcription to mRNA or the translation of mRNA to 
proteins is suppressed. Therefore, antisense oligonucleotides 
therapeutics can be used to block the expression of abnormal genes 
and have been investigated for different medical applications, such 
as oncologic, infectious and cardiovascular diseases.  
RNA interference 
RNA interference (RNAi) reveals great therapeutic potential as a 
post-translation gene regulation process for a variety of diseases, 
including genetic disorders, autoimmune diseases, viral infections, 
and cancer [25, 26]. 
Types of RNAs 
Small interfering RNA 
The small interfering RNA (siRNA) or silencing RNA is a double-
stranded RNA molecule with 20-25 bp that has a major role in RNAi 
pathways, where it interferes with the expression of specific genes 
with complementary nucleotide sequences [27]. RNA interference is a 
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type of regulatory mechanism that most commonly occurs in the 
cytoplasm of most eukaryotic cells to control gene activity [28, 29]. In 
the process of RNA interference, long double-stranded RNA is cleaved 
into shorter double-stranded RNA segments (siRNA) by the dicer 
proteins. After cellular entry, the siRNA duplex is assembled into large 
protein assemblies, called the RNA-induced silencing complexes 
(RISC) where the sense strand of siRNA is removed and cleaved by the 
RNase H-like activity of Ago-2 (cleavage-dependent pathway, member 
of the argonaut family of proteins) [30] and is a major component of 
RISC [31]. The other members of Argonaut family, like Ago-1, Ago-3, 
and Ago-4, do not have specific endonuclease activity, and they 
function through a cleavage-independent pathway [32]. 
Small hairpin RNA (shRNAs) 
shRNAs is a type of RNA consisting of 25 to 29 bases and a loop of 4-23 
nucleotides sequence that can induce gene silencing through RNAi 
[33]. shRNA is processed in the cytoplasm by the dicer protein to 
remove the loop to produce siRNA, which then forms RISC followed by 
subsequent cleavage of the target mRNA [34]. Bifunctional shRNA 
employs two shRNA, one with the perfect match for cleavage-
dependent RISC loading and the second with mismatched sense 
strands (at the central location) for cleavage-independent RISC loading 
[35] has been designed to enhance the efficiency of shRNA. 
MicroRNA 
MicroRNA (miRNAs) are mature and short (20-24 nucleotides) 
single-stranded, non-coding RNAs that bind to partially 
complementary sites, called miRNA binding sites. miRNA silences 
gene expression by affecting the stability of target mRNAs or via 
translational repression. miRNAs are transcribed from DNA initially 
as long primary transcripts termed as “pri-miRNA” comprised of an 
RNA hairpin structure which is cleaved from the pre-miRNA by the 
nuclear microprocessor complex and the endonuclease drosha 
complex in the nucleus, which subsequently gives rise to precursor 
miRNA termed as “pre-miRNA” [36]. The pre-miRNA is transported 
from the nucleus to the cytoplasm by exportin-5 [37] and is further 
cleaved by the endonuclease dicer into short double-stranded RNA, 
in which one strand is the mature miRNA and its counterpart is 
known as the miRNA [38]. 
Vectors in nucleic acid delivery 
Vectors are the carriers that act as the delivering vehicles for the 
drugs, nucleic acid, and various biotechnological active substances. 
For delivering nucleic acids to the cells, these are broadly divided 
into two categories named viral and non-viral vectors. NA can be 
delivered to patients by either ex vivo or in vivo methods. In vivo 
methods involve vector delivery, through intravenous injection, or 
direct local implantation, to a specific tissue. In contrast, ex vivo 
methods comprise an initial removal of cells from the patient, 
followed by their in vitro genetic manipulation and subsequent 
reintroduction of modified cells to the patient [39]. Ex vivo therapy is 
considered to be safer and more effective than in vivo therapy 
because cells modified in vitro can be selected and amplified, before 
patient reinfusion. However, when target cells are difficult to collect 
or manipulate in vitro, the in vivo procedure remains the only 
suitable option [40]. 
Viral vectors 
Viral vectors are the most efficient vehicles for NA transfer due to their 
ability to infect a large number of cells. Since viruses have evolved 
natural mechanisms to deliver their genetic material into cells, they are 
excellent vectors to deliver transgenes [41]. Briefly, viral vectors consist 
of viruses that are modified to be replication-incompetent but can 
deliver NA into the cells [42]. The use of viral vectors for NA delivery 
presents several disadvantages, such as [43, 44]:  
• They might alter more cells than the intended ones;  
• The transgene can be inserted in the wrong location of the DNA 
strand, causing damage;  
• The gene can be over-expressed;  
• The modified virus can cause body inflammation or trigger an 
immune reaction;  
• The virus can be transmitted to other individuals or to the 
environment. 
Apart from all these disadvantages, the majority of the viral vectors 
used in human clinical trials appear to be safe and well-tolerated by 
patients [44].  
Converting a virus into a vector 
In the life cycle of a virus, two distinct phases should be considered: 
infection and replication [45]. Viral vectors are parasitic particles, 
which are naturally capable of entering in the host cells and 
transferring to them their genetic sequences. Viruses become 
replication-incompetent by deletion of a portion of the genetic 
sequence essential for viral propagation and subsequent replacement 
of this sequence by a transgene [39]. The construction of a viral vector 
requires sufficient knowledge and an effective strategy. The viral life 
cycle and its genetic sequence must be well known in order to delete 
non-essential and virulent genes. The genome deletion enables the 
construction of an on-pathogenic vector, which is unable to infect the 
patient but maintains its replicative ability [46]. The viral genome 
comprises genes and cis-acting gene regulatory sequences. To produce 
a viral vector, the genes and cis-acting sequences should be separated 
into distinct NA molecules, to prevent their reconstitution in 
productive viral particles and to allow the maintenance of the efficacy 
and safety of the system [47]. As there are no universally applicable 
ideal viral vector available, several characteristics of each vector and 
type of disease need to be defined before making decisions about 
which vector type should be applied [48]. Considerations regarding 
viral vectors include the ability to attach and enter into the target cells, 
the ability to transfer the NA to the nucleus, the ability of NA being 
expressed in the nucleus for a prolonged period of time and the lack of 
toxicity [49]. Accordingly, an ideal NA delivery vector should have the 
following characteristics [50]:  
• High specificity;  
• Efficient NA delivering, in the amount needed for clinical 
application;  
• Unrecognized by the immune system;  
• Ability to be purified in high concentrations;  
• Safe for the patient and also for the environment;  
• Express the gene during the required period. 
The purified vectors generally are stored either refrigerated or frozen, 
and display usable shelf lives of more than 2 y [51]. There are five main 
classes of viral vectors commonly used for NA delivery (fig. 4). These can 
be categorized in two groups, according to whether their genomes 
integrate into host cellular chromatin (retrovirus and lentiviruses), or 
persist in the cell nucleus mainly as extra-chromosomal episomes 
(adenovirus, adeno-associated virus and herpes simplex virus) [52]. 
Besides these, many other viral vectors have been used for NA delivery 
(e. g. poxvirus, alphavirus, human cytomegalovirus) [44]. 
 
 
Fig. 4: Classification of viral vectors 
Kumari et al. 
Int J App Pharm, Vol 13, Issue 2, 2021, 26-32 
29 
Retrovirus 
Retrovirus are RNA-based vectors that replicate through a DNA 
intermediate and comprise both a capsid and an envelope protein 
containing a lipid bilayer. The most widely characterized retroviral 
vector is the Moloney murine leukemia virus (MoMuLV), which was 
the first used for the treatment of adenosine deaminase severe 
combined immunodeficiency (ADA-SCID) [53]. The more simple 
class of retroviruses contains three major coding segments gag 
(codes for core viral protein), pol (codes for reverse transcriptase) 
and env (codes for viral envelope proteins). At either end of the viral 
genome are the long terminal repeat (LTR) sequences, which harbor 
powerful promoter and enhancer regions and sequences required to 
promote integration into the host DNA [39, 51, 54]. 
Virus infection begins with the binding of the viral envelope 
glycoprotein to cell receptors. Within the cytoplasm, the viral 
reverse transcriptase enzyme converts the RNA genome into linear 
double-stranded DNA, which is randomly integrated into the host 
cell genome [40, 51]. The main concerns in using recombinant 
retroviruses are the risk of accidental random integration into the 
host chromosome, resulting in deleterious effects, such as the 
activation of certain proto-oncogenes by insertional mutagenesis, or 
inactivation of other tumor suppressor genes [41]. Through 
recombinant DNA techniques, the endogenous viral genes gag, pol 
and env required for the reproduction of retrovirus genome are 
removed and replaced by the exogenous gene of interest. The 
advantages of using retroviral vectors include:  
• Stable integration into the host genome;  
• Efficient gene transfer by generating enough viral titre 
• Ability to infect several different cell types;  
• Capacity to transport foreign genes of reasonable sizes (<8 kb). 
In contrast, this type of vectors also present some disadvantages [44, 
45], including:  
• Poor stability to transport NA;  
• Risk of damage during purification and concentration process;  
• Relatively low carrying capacity;  
• Inability to infect non-dividing cells;  
• Possible insertional mutagenesis. 
Lentivirus 
Lentivirus, such as human immunodeficiency virus type 1(HIV-1), 
are a subcategory of the retrovirus family, which are capable of 
infecting non-dividing cells [45]. This ability of lentivirus is due to 
their targeting the nucleus without the requirement of mitosis [44]. 
Despite all retrovirus have only three structural genes, the lentivirus 
have two additional genes (tat and rev) and four accessory genes 
(vif, vpu, nif, vpr). Although lentivirus can integrate in the host 
genome, their integration sites are significantly more restricted than 
for other retroviruses [56]. Lentivirus vectors were developed with 
the aim to become the substitutes of onco-retrovirus, due to their 
ability of transgene expression and enhanced safety [57]. These 
vectors have been successfully applied in gene therapy because they 
offer greater advantages over the other retrovirus counterparts [58]. 
Lentivirus vectors have the advantages of long-term transgene 
expression, low immunogenicity, and the ability to accommodate 
larger transgenes. Furthermore, due to their natural integration 
ability, lentivirus have a lot of potential for central nervous system 
gene delivery [59]. 
Adenovirus 
Adenoviruses contain a linear, double-stranded DNA genome, 
around 36 kb in size, package within a non-enveloped icosahedral 
capsid. The adenoviral infection involves binding of the viral capsid 
proteins existing in specific receptors of host cells and subsequent 
internalization, by receptor-mediated endocytosis. However, unlike 
retroviruses, upon cellular infection, adenoviral DNA becomes 
localized in the nucleus as an episomal element but does not 
integrate the host cell genome, which means that there is a low risk 
of insertional mutagen city [39, 60].  
The advantage of these viruses is their ability to infect target cells, 
which greatly minimizes the risk of insertional mutagenesis. 
However, the failure of the adenoviral-based DNA to integrate into 
the host cell generally means that its survival and, therefore, the 
duration of gene expression is limited [51]. Studies on the 
development of adenoviral vectors brought significant progress in 
the target cell specificity, long-term expression of the transgene, 
immunogenicity and in vivo toxicity [61].  
Adenovirus gene delivery systems have been used more frequently 
for in vivo approaches than retrovirus-based systems. Although early 
generations of adenovirus showed toxic side effects and immune 
responses, newer second and third-generation vectors with many of 
the genes deleted have demonstrated significant improvements [48]. 
Adenovirus possesses strong tropism to epithelial tissues and was 
the first viral vectors tested for gene therapy of cystic fibrosis [62]. 
Adenoviral vectors have also been used for treating peripheral 
vascular diseases and coronary artery diseases [44, 47]. Moreover, 
apart from using adenovirus vectors as carriers for transgenes, these 
virus itself provides antitumor activity, by targeting tumor cells with 
the defective p53 protein [44].  
Adeno-associated virus 
Adeno-associated virus are small, non-enveloped, linear single 
stranded DNA virus, which belong to the Parvoviridae family. This 
virus is replication-defective and to replicate within a host cell 
nucleus needs a helper virus, such as adenovirus or herpes virus [49, 
63]. These systems provide a mechanism of gene transfer into non-
dividing cells, and also seem to facilitate the long-term expression of 
the transferred genetic material. In contrast to adenovirus, the NA 
transferred by adeno-associated viruses appears to be integrated 
into the host cell genome [51]. 
Adeno-associated virus present some advantages over other viral 
vectors, since they are non-pathogenic, non-immunogenic, and are 
able to infect a wide variety of dividing and non-dividing cells [39, 
44, 49]. Besides, adeno-associated virus are unique among virus that 
have been used for gene therapy, because although they are found in 
human population, they do not appear to be associated with any 
disease. The small size and simplicity of the vector particle enables 
the systematic administration of high doses of the vector, without 
eliciting acute inflammatory responses or toxic side effects [52]. 
However, the restricted tropism of adenoassociated virus and its 
relatively small capacity for insertion of transgenes (ranging from 
4.1 to 4.9 kb) are some examples of the limitations of this viral 
vector [39, 44, 49]. In contrast, it has been shown that these vectors 
are suitable for both in vitro and in vivo gene transfer into muscle, 
brain, neurons and liver cells [44].  
Herpes simplex virus 
Herpes simplex virus are a class of double-stranded DNA virus, 
characterized by a large genome (152 kb), belonging to the family 
Herpes viridae, which have the ability to infect cells of the nervous 
system [45]. Herpes virus are very promising vehicles for gene 
transfer, because of their ability to persist, after a primary infection, in 
a state of latency where the disease is absent in human hosts with 
normal immune status [47]. These vectors are of interest mainly 
because of its large packaging capacity for transgenes, allowing for the 
inclusion of more than one transgene and also large transcriptional 
regulatory elements and its natural tropism toward neuronal cells. 
Different aspects of the herpes virus make them attractive for using 
as vectors for gene therapy [64]: highly infectious capacity;  
• Virus receptors are widely expressed on the surface of 
numerous cell types;  
• Non-dividing cells may be efficiently infected and transduced;  
• Recombinant virus can be easily produced to high titer and purity;  
• The latent behavior of the virus may be exploited for stable long-
term expression of therapeutic transgenes in neurons. 
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Poxvirus and other viral vectors 
A special emphasis should also be given to poxvirus, which are large 
complex enveloped viruses with an enveloped double-stranded DNA 
genome of approximately 190 kbp in length. The orthopoxvirus 
subfamily includes vaccinia virus, which had a crucial role in one of 
the greatest achievements in medicine: the eradication of smallpox. 
One of the main advantages of these viruses is their high insertion 
capacity for multiple foreign genes. They have the ability to integrate 
more than 25 kbp heterologous DNA [44, 65]. Numerous inherent 
biological properties of vaccinia and other poxvirus make them ideal 
to express foreign antigens and so they have been used in many 
vaccine trials [66] and in the treatment of cancers [67]. 
Recently, a new class of oncolytic poxvirus has been developed, 
which combines targeted and armed approaches for treating cancer. 
Initial preclinical and clinical results show that products from this 
therapeutic class can systemically target cancers through a highly 
selective mechanism of action [68]. 
Poxvirus has several advantages as oncolytic therapeutic viral 
vectors, including  
• Safety in humans,  
• Ease of production,  
• Stability of virus preparations, and  
• Feasibility of genetic manipulation for transgene expression  
• Replication takes place entirely in the cytoplasm of an infected 
cell, and thereby viral genome integration into host chromosomes 
does not occur. 
Four poxvirus; VV (Orthopoxvirus), MYXV (Leporipoxvirus), 
racoonpoxvírus (Orthopoxvirus), and yaba-like disease virus (Yata 
poxvirus), from three different genera have been investigated. All of 
these viruses undergo productive lytic replication in most human 
cancer cells. The most frequently used vectors are based on Semliki 
Forest virus (SFV), Sindbis virus (SIN) and Venezuelan Equine 
Encephalitis (VEE) virus. Among others, human cytomegalovirus, 
influenza virus, and foamy virus have also been used to engineer 
vectors with feasible insertion capacities, expression efficiencies and 
cell tropism of viral infection [44].  
Hybrid or chimeric vectors 
Viral vectors are effective to transport genetic material within the 
cells. However, clinical trials showed that these vectors have some 
inherent limitations for therapy, namely, immunogenicity, toxicity, 
limited loading capacity, and failure of long-term adequate 
transgene expression. To overcome these drawbacks, attempts have 
been made, in order to combine the best characteristics of different 
viruses, by means of hybrid vectors [69]. 
These systems are more complex than conventional viral vectors, 
because they have components of two or more viruses or are 
combined with other proteins or genetic components, with the 
following objectives [40, 69]. 
• To target specific tissues or cell types;  
• To accommodate large transgenes and regulatory elements;  
• To achieve stable and regulated transgene expression;  
• To retain high transduction efficiency and titers while minimizing 
undesired toxicity or immune responses. 
Adenovirus and adeno-associated virus have attractive and 
complementary properties that can be exploited for gene transfer 
purposes. Adenoviruses combined with adeno-associated virus 
allowed the construction of hybrids with site-specific gene 
integration properties [70]. The hybrid adenovirus-retrovirus vector 
is based on the addition of retroviral integration machinery into 
adenoviruses, which maintains the attributes of these viruses for in 
vivo gene delivery and of retroviruses for long-term transgene 
expression [71]. Herpes simplex-adeno-associated virus hybrid 
vectors also proved the capacity to extend transgene expression in 
non-dividing hepatocytes and neurons in vitro [72] and in vivo [73]. 
Vectors based on hybrids consisting of adeno-associated virus types 
2 and 5 were evaluated for muscle-directed gene transfer. Hildinger 
et al. showed that these types of hybrid vectors may have a number 
of advantages for muscle gene therapy application [74]. 
CONCLUSION 
The extracellular, intracellular and other barriers offer added hurdles in 
the delivery of DNA, RNA, and antisense oligonucleotides to the affected 
cells. Another challenge, which has an equal impact to the delivery of 
genes, is the unstable nature of the DNA under the influence of the 
enzymes DNAase and RNAase. Similar to drug delivery, the 
encapsulation and/or conjugation of genes to the polymeric carriers has 
always been advantageous in terms of the effective transfection and 
delivery to the targeted cells. The size has played a crucial role in this 
regard and the smaller the size, the more the chance of the vector to be 
bypassed from the mononuclear phagocytic system of the body, which 
would, in turn, increase its overall circulation time and stability. Gene 
delivery has emerged as a promising approach for the treatment of 
complex disorders such as cancer, Alzheimer’s, AIDS and related 
disorders since 1996. Future studies may include the co-delivery of 
antibodies with the relevant DNA or RNA.  
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